Daniele Santini | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer	FUTURE ONCOLOGY	2016
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy	SCIENTIFIC REPORTS	2016
New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	2016
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?	ONCOTARGET	2016
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life”	ANNALS OF ONCOLOGY	2015
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety	EUROPEAN JOURNAL OF CANCER	2015
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study	EUROPEAN UROLOGY	2015
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2015
Different Levels of Alkaline Phospatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions	BLOOD	2015
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs)	ANNALS OF ONCOLOGY	2015
Targeted therapies for bone metastases	Targeted Therapies for Solid Tumors	2015
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients	ANNALS OF ONCOLOGY	2015
Natural history of skeletal disease in primary biliary cancers. National survey on behalf of GICO group (Gruppo Italiano Colangiocarcinoma – Onlus)	ANNALS OF ONCOLOGY	2015
Targeted therapies for bone metastases	Targeted Therapies for Solid Tumors	2015
Interventional radiologist's perspective on the management of bone metastatic disease	EUROPEAN JOURNAL OF SURGICAL ONCOLOGY	2015
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence	BREAST CANCER RESEARCH	2015
Emerging kinase inhibitors of the treatment of gastric cancer	EXPERT OPINION ON EMERGING DRUGS	2015
Deregulation of dicer and mir-155 expression in liposarcoma	ONCOTARGET	2015